Bal Pharma Ltd

Bal Pharma Ltd

₹ 91.2 -4.15%
28 Mar - close price
About

Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]

Key Points

Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.

  • Market Cap 144 Cr.
  • Current Price 91.2
  • High / Low 132 / 64.6
  • Stock P/E 41.4
  • Book Value 40.0
  • Dividend Yield 1.10 %
  • ROCE 9.56 %
  • ROE 4.20 %
  • Face Value 10.0

Pros

  • Company has been maintaining a healthy dividend payout of 39.6%

Cons

  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -0.38%
  • Company has a low return on equity of 7.22% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
63.03 70.81 70.83 67.17 69.17 74.05 69.84 75.31 76.62 82.45 70.39 92.54 81.66
57.10 64.47 63.35 60.84 62.95 70.60 64.80 69.53 70.47 74.29 63.95 84.84 73.87
Operating Profit 5.93 6.34 7.48 6.33 6.22 3.45 5.04 5.78 6.15 8.16 6.44 7.70 7.79
OPM % 9.41% 8.95% 10.56% 9.42% 8.99% 4.66% 7.22% 7.67% 8.03% 9.90% 9.15% 8.32% 9.54%
0.19 0.73 0.14 0.56 0.75 3.70 0.24 0.05 0.46 0.19 0.16 0.14 0.10
Interest 2.89 3.11 2.97 2.63 2.36 2.45 2.37 2.86 3.11 3.85 3.64 3.82 3.66
Depreciation 2.03 3.44 2.19 2.21 2.21 2.42 2.23 2.37 2.45 2.09 2.53 2.42 2.96
Profit before tax 1.20 0.52 2.46 2.05 2.40 2.28 0.68 0.60 1.05 2.41 0.43 1.60 1.27
Tax % 66.67% -576.92% 32.93% 31.71% 80.42% 3.95% 58.82% 78.33% 43.81% 32.78% 79.07% 39.38% 33.07%
0.40 3.53 1.65 1.39 0.48 2.19 0.28 0.12 0.59 1.62 0.09 0.97 0.85
EPS in Rs 0.23 2.42 1.09 0.93 0.43 1.33 0.18 0.07 0.36 1.02 0.05 0.61 0.56
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
106 114 179 187 198 229 211 225 171 251 281 304 327
103 104 161 170 183 214 194 207 166 226 257 279 297
Operating Profit 3 10 18 17 15 15 17 18 5 25 24 25 30
OPM % 3% 9% 10% 9% 7% 6% 8% 8% 3% 10% 9% 8% 9%
5 1 1 1 1 3 2 1 2 1 5 1 1
Interest 6 7 7 7 6 8 9 13 13 12 11 12 15
Depreciation 3 3 5 7 7 6 7 6 8 10 9 9 10
Profit before tax -1 1 7 5 3 3 3 -0 -14 4 9 5 6
Tax % -57% 60% 23% 25% 90% 114% 87% 1,175% 5% -15% 38% 45%
-1 0 5 4 1 -0 0 2 -13 5 6 3 4
EPS in Rs -1.36 0.39 4.56 2.82 1.10 1.24 1.96 2.67 -8.62 3.20 3.78 1.64 2.24
Dividend Payout % 0% 0% 22% 35% 91% 81% 51% 37% 0% 31% 26% 61%
Compounded Sales Growth
10 Years: %
5 Years: 8%
3 Years: 21%
TTM: 11%
Compounded Profit Growth
10 Years: %
5 Years: 47%
3 Years: 30%
TTM: 19%
Stock Price CAGR
10 Years: 11%
5 Years: 5%
3 Years: 19%
1 Year: 42%
Return on Equity
10 Years: %
5 Years: 1%
3 Years: 7%
Last Year: 4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 10 10 11 13 13 14 14 14 14 15 15 16 16
Reserves 25 26 37 40 40 48 51 52 38 39 43 48 48
54 58 51 49 89 93 110 124 118 110 104 131 141
34 41 56 61 69 78 86 71 68 76 99 116 126
Total Liabilities 124 135 155 164 211 233 260 261 238 240 261 311 330
50 48 55 52 56 60 71 70 71 69 67 76 76
CWIP 0 0 0 1 4 2 0 4 3 0 2 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
74 87 99 111 151 172 188 187 164 172 192 235 254
Total Assets 124 135 155 164 211 233 260 261 238 240 261 311 330

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-5 5 13 15 -19 6 1 8 23 22 27 -2
5 -2 -7 -5 -14 -8 -4 -8 -5 -6 -9 -22
1 -2 -8 -7 32 -6 4 0 -20 -17 -17 24
Net Cash Flow 0 1 -2 2 -1 -8 1 -0 -2 0 0 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 110 118 93 88 105 99 111 105 106 98 98 113
Inventory Days 174 191 122 132 145 172 240 217 292 146 162 207
Days Payable 129 157 129 142 163 171 182 147 167 114 143 167
Cash Conversion Cycle 155 153 86 78 87 100 168 175 231 130 117 153
Working Capital Days 137 141 98 92 142 140 163 166 180 129 109 134
ROCE % 4% 8% 11% 7% 8% 8% 7% -0% 10% 12% 10%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
44.98% 44.84% 46.87% 49.57% 49.57% 52.00% 52.00% 51.61% 51.61% 51.61% 51.61% 51.24%
0.00% 0.00% 0.15% 0.31% 0.31% 0.30% 0.20% 0.18% 0.17% 0.17% 0.14% 0.13%
55.02% 55.16% 52.98% 50.12% 50.12% 47.71% 47.80% 48.21% 48.23% 48.23% 48.25% 48.64%
No. of Shareholders 12,64816,53116,31916,04916,22316,31716,17016,46616,02915,86915,52915,060

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls